Sana Biotechnology (NASDAQ:SANA) Releases Earnings Results, Beats Estimates By $0.02 EPS

Posted by Francis Steltz on Aug 13th, 2026

Sana Biotechnology (NASDAQ:SANA – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.02, FiscalAI reports.

Sana Biotechnology Stock Performance

NASDAQ SANA opened at $3.77 on Thursday. Sana Biotechnology has a 52-week low of $2.61 and a 52-week high of $6.55. The stock has a market cap of $1.13 billion, a PE ratio of -4.96 and a beta of 2.16. The firm has a 50-day moving average of $3.33 and a 200-day moving average of $3.46.

Hedge Funds Weigh In On Sana Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in the company. Virtu Financial LLC lifted its holdings in Sana Biotechnology by 189.4% during the 4th quarter. Virtu Financial LLC now owns 119,312 shares of the company’s stock worth $486,000 after purchasing an additional 78,088 shares during the last quarter. Invesco Ltd. increased its position in Sana Biotechnology by 24.1% during the fourth quarter. Invesco Ltd. now owns 561,835 shares of the company’s stock worth $2,287,000 after acquiring an additional 109,078 shares during the period. XTX Topco Ltd raised its position in shares of Sana Biotechnology by 9.9% in the fourth quarter. XTX Topco Ltd now owns 117,376 shares of the company’s stock valued at $478,000 after buying an additional 10,581 shares in the last quarter. VARCOV Co. bought a new position in Sana Biotechnology in the fourth quarter valued at approximately $264,000. Finally, Virtus Investment Advisers LLC grew its position in Sana Biotechnology by 15.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 51,756 shares of the company’s stock valued at $211,000 after acquiring an additional 6,958 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on SANA shares. Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Weiss Ratings raised Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. Finally, Rodman & Renshaw began coverage on shares of Sana Biotechnology in a report on Monday, May 11th. They set a “buy” rating and a $16.00 target price on the stock. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Sana Biotechnology currently has a consensus rating of “Moderate Buy” and an average target price of $9.50.

Check Out Our Latest Analysis on SANA

Sana Biotechnology Company Profile

(Get Free Report)

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.